BROADCASTS.com

b'

ENA Respiratory ( https://enarespiratory.com/ ) is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia Dr. Ruth Tal-Singer, Ph.D., Medicine Development Leader, ENA Respiratory, is an internationally recognized healthcare leader and clinical scientist with extensive Research and Development experience including recent roles as Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals where during her career she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. Her vision led to the creation of World Bronchiectasis Day, observed on July 1. Dr. Tal-Singer\\u2019s idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations. As the leader of COPD360Net, the COPD Foundation\\u2019s digital health, medical devices, and therapeutics development accelerator network, she championed the partnership between ENA Respiratory and the COPD Foundation and served as a member of its Board of Directors on behalf of the COPD Foundation until March 31, 2023. Dr. Tal-Singer has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. As a researcher, Dr. Tal-Singer has authored 180+ peer-reviewed papers including highly cited scientific publications. She has a Doctor of Philosophy (PhD), Molecular Biology / Microbiology, from University of Pennsylvania, did post-doctoral work at the Wistar Institute, and continues to lecture at the Institute of Translational Medicine and Therapeutics at Penn. Dr. Scott M. White, M.D., Chief Medical Officer, ENA Respiratory, is an infectious diseases physician who has spent over 17 years working in the pharmaceutical and biotech industry. Most recently he served as Vice President Clinical Development for the infectious diseases therapeutic area of Inovio Pharmaceuticals where he was responsible for the clinical development of immunotherapeutic and prophylactic DNA-based vaccines. Prior to this he was a Physician Project Leader for GlaxoSmithKline. In this role he was accountable for several development programs spanning pre-candidate selection through early stage clinical development of assets in the therapeutic areas of infectious diseases, hematology, and dermatology. During this time at GlaxoSmithKline, in collaboration with AstraZeneca, the EU Innovative Medicines Initiative, and medical and scientific leaders throughout Europe, he led the establishment of COMBACTE; a European antibacterial clinical trial network supporting the development of antibiotics targeting resistant organisms.\\xa0 Dr. White has his M.D. from Pennsylvania State University College, and did an Infectious Diseases Fellowship at University of Pittsburgh School of Medicine.\\xa0